OCM Participants Consider Costs of 2-Sided Risk

OncLive - Software That Does More Than Document Care

After 3 years of struggling to meet targets for improved care quality and cost efficiency, many of the 175 practices that have remained in the Oncology Care Model (OCM) of the Centers for Medicare & Medicaid Services (CMS) have a decision to make: Assume a share of the downside risk for failure to meet financial targets or exit the OCM by December 3.

Read More…

“Not So Different”: Is There a Role for Biosimilars in Value-Based Models?

the center for biosimilars

As fee-for-service models give way to value-based healthcare delivery models, US providers and patients alike can hopefully look forward to lower healthcare costs, increased quality of care, and improved outcomes. But what role will biosimilars have to play in value-based care? This week on the podcast, we’re speaking with Jeffrey Scott, MD, chief medical officer of Integra Connect, about this issue.

Read More…

Predictive Analytics Can Help Hospices Reach Patients Sooner

Hospice News Logo

Predictive analytics systems are gaining ground in the hospice and palliative care fields as a means to identify patients in need of service earlier in the course of their illness. Providers and payers are increasingly using these systems to build their census and ensure that patients and families receive the right care at the right time.

Read More…

Survey Shows Growing Use of Genetic Testing in Prostate Cancer Management in the Community

Targeted Oncology

It is known that genetic testing plays a role in the management of prostate cancer, but community practices are still trying to understand and overcome the challenges for increased adoption and find better ways to decide which patients require hereditary testing, how to utilize the test information, and when genetic counseling is needed. Raoul S. Concepcion, MD, covered this topic during a presentation at the 2019 Prostate Cancer Consensus Conference.

Read More…

Determining Factors of Poor OCM Performance: An Analysis of PP4

journal of clinical pathways - Implementing Technology in Community-Based Practice Offers Multiple Advantages

In the past month, the Centers for Medicare and Medicaid Services (CMS) shared the results of Oncology Care Model (OCM) performance period 4 (PP4) with participating practices. Charles Saunders, MD, chief executive officer, Integra Connect, provides a brief commentary on a surprising trend in the OCM PP4 results, considerations for practices contemplating two-sided risk, and how predictive analytics will help practices meet their bottom line moving forward.

Read More…

Dissecting OCM Performance Period 4 Results and Their Implications

AJMC - Managed Markets Network

With Oncology Care Model performance period 4 results out now, it’s a transformative point in the model in which practices that have not yet achieved a performance-based payment have to either enter 2-sided risk or leave the model. To dive into the most recent results and their implications, we spoke with Charles Saunders, MD, chief executive officer of Integra Connect.

Read More…

The Evolution of Oncology Clinical Pathways Utilization

The health care sector has undergone a shift in the way care is delivered, in the way outcomes are measured, and in how services are reimbursed. The movement has been toward more data-driven science with an emphasis on high-quality outcomes at less cost.

Payers and providers alike seek to ensure clinical decisions are based foremost on the best and latest evidence across all settings...

Read More…

Challenges to leveraging real-world evidence for FDA approval

The Cancer Letter - Logo

The number of approved cancer therapies continues to rise, with 63 cancer drugs launched within the past five years.

This proliferation of new drugs on the market, coupled with biosimilars getting fast-tracked by the FDA, has resulted in mounting competitive pressures for the biopharma industry. In response, the industry has been eagerly embracing the idea of leveraging real-world evidence as a means to reduce time to market, whether by supporting the repurposing of existing drugs for new indications or for post-approval studies.

Read More…

Value-Based Care Tackles Oncology Costs

managed healthcare executive

Oncology spending has grown unabated for years, with systemic cancer costs forecast to grow by as much as 40% from 2010 to 2020, reaching $173 billion, according to Community Oncology Alliance (COA). While this growth can be attributed to improved longevity, earlier detection and changes in care settings—such as the increased use of hospital settings for patient care in lieu of less-expensive, community-based settings—novel therapies continue to remain a primary cost driver.

Read More…

Mind the gap: Precision medicine shortcomings in NSCLC

Healio - HemOnc Today

This year’s ASCO Annual Meeting included several major successes that should translate to new molecular targets in advanced non-small cell lung cancer, but recent real-world evidence should lead us to take a hard look in the mirror and realize we’re failing to deliver on the promise of the treatments we already have.

Read More…